{
  "title": "Paper_909",
  "abstract": "pmc Adv Healthc Mater Adv Healthc Mater 379 blackwellopen ADHM Advanced Healthcare Materials 2192-2640 2192-2659 pmc-is-collection-domain yes pmc-collection-title Wiley Open Access Collection PMC12477566 PMC12477566.1 12477566 12477566 40702844 10.1002/adhm.202503281 ADHM70038 1 Research Article Research Article Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics Tam Nok Yin  1 Wang Xiaoqi  2 Chan Grace Chung Yan  1  2 Kong Wai Po  3 Chau Wai Yin  1 Fu Xiuqiong  2 Wong Kwokâ€Yin  3 Lung Hong Lok  1 Yu Zhiâ€Ling  2 zlyu@hkbu.edu.hk Aik Wei Shen https://orcid.org/0000-0003-4414-173X  1 aikweishen@hkbu.edu.hk   1 Department of Chemistry Hong Kong Baptist University Kowloon Tong Kowloon Hong Kong SAR China   2 School of Chinese Medicine Hong Kong Baptist University Kowloon Tong Kowloon Hong Kong SAR China   3 State Key Laboratory of Chemical Biology and Drug Discovery Department of Applied Biology and Chemical Technology The Hong Kong Polytechnic University Kowloon Hong Kong SAR China * aikweishen@hkbu.edu.hk zlyu@hkbu.edu.hk 23 7 2025 26 9 2025 14 25 497748 10.1002/adhm.v14.25 e03281 08 7 2025 02 7 2025 29 09 2025 30 09 2025 30 09 2025 Â© 2025 The Author(s). Advanced Healthcare Materials published by Wileyâ€VCH GmbH https://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ Abstract RNAi therapeutics can potentially address undruggable diseases. However, their full potential is stymied by delivery challenges. An siRNA delivery platform by remodeling the human U4 small nuclear ribonucleoprotein complex (snRNP) is developed. This remodeled proteinâ€siRNA complex (SmiRNP) serves as a biocompatible, modular, and customizable platform for attaching desired functional modules to overcome delivery hurdles. Here, it is demonstrated that the SmiRNP complex, by using siRNA against KRAS KRAS A modular and customizable RNAi therapeutics delivery platform composed of a pseudosymmetric human RNA binding proteinâ€siRNA complex (SmiRNP) is developed. By fusing a targeting module and an endosomal escape peptide onto the delivery platform, SmiRNP successfully delivered siRNA to silence the KRAS KRAS proteinâ€based delivery agent ribonucleoprotein complex RNAi therapeutics siRNA delivery pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes source-schema-version-number 2.0 cover-date September 26, 2025 details-of-publishers-convertor Converter:WILEY_ML3GV2_TO_JATSPMC version:6.6.4 mode:remove_FC converted:29.09.2025  N. Y. Tam X. Wang G. C. Y. Chan Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics Adv. Healthcare Mater. 14 25 2025 14 e03281 10.1002/adhm.202503281 PMC12477566 40702844 1 Introduction RNA interference (RNAi) therapeutics are a type of gene therapy that uses small interfering RNAs (siRNAs) to silence target genes. siRNAs are typically short doubleâ€stranded RNAs (dsRNA) with 21â€“23 nucleotides. Once introduced into the cell, siRNAs will be processed and loaded onto the RNAâ€induced silencing complex (RISC), which will cleave mRNAs complementary to the guide RNA strand, thus leading to gene silencing. [  1 ] [  2 ] [  3 ] [  4 ] [  5 ] [  6 ] [  5  6 ] Here, we developed a proteinâ€based RNAi therapeutics delivery platform that is modular and customizable, potentially complementing existing delivery technologies in targeting extrahepatic tissues. Our siRNA delivery platform contains a heteroheptameric scaffold modified from a Uâ€rich small nuclear ribonucleoprotein complex (snRNP), which consists of 7 Sm proteins binding to a Uâ€rich consensus sequence inserted into the siRNA. We henceforth call it Smâ€siRNA ribonucleoprotein complex (SmiRNP). Each Sm protein is unique and has 2 termini (N and C) available for protein fusion. The multimeric core serves as a scaffold for fusing up to possibly 14 functional protein modules to target different tissues and cross biological hurdles. The delivery platform is largely made of human proteins for biocompatibility. As proofâ€ofâ€concept, we demonstrate that the SmiRNP can deliver siRNA to silence KRAS 2 Results and Discussion 2.1 Design and Reconstitution of SmiRNP We envisioned the human small nuclear ribonucleoprotein complexes (snRNPs) as a starting point for engineering a modular siRNA delivery agent because snRNPs contain small nuclear RNAs (snRNAs), [  7 ] [  7  8 ] [  7a,d ] [  7a,d ] [  7  9 ] To remodel a snRNP into a ribonucleoprotein complex that can bind siRNA (SmiRNP), we modified the U4 snRNP core ( Figure  1 KRAS S2 [  7  10 ] [  11 ] [  12 ] 1â€95 1â€95 1â€95 Figure  2 2A Figure 1 Design Concept of SmiRNP as an siRNA delivery agent. SmiRNPs are reconstituted by complexing siRNA containing a Uâ€rich sequence recognized by a combination of seven different Sm core proteins (SmD1/SmD2, SmD3/SmB 1â€95 1â€95 Figure 2 Size exclusion chromatography and negative stain electron microscopy characterization of the in vitro reconstituted SmiRNPâ€EGFâ€H5E. A) Size exclusion chromatography profile of the in vitro reconstituted SmiRNPâ€EGFâ€H5E and SDSâ€PAGE analysis of the fractions from the major peak (ï¼Š). M, protein molecular weight marker; red line, UV 260Â nm absorbance; blue line, UV 280Â nm absorbance. B) A representative raw negative stain electron micrograph of SmiRNPâ€EGFâ€H5E. The scale bar indicates 200Â nm. C) Representative 2D class averages of SmiRNPâ€EGFâ€H5E. Scale bar indicates 80Â Ã…. D) Top (left) and side (right) views of the model of the U4 snRNP core (PDB ID 4WZJ) [  7a ] Ïƒ [  13 ] [Correction added on August 5, 2025, after first online publication: Figure 2 To further verify that the Sm proteins bind to the Sm sequence on the 5â€²â€end of the antisense strand of siKRAS, we analyzed, by size exclusion chromatography, the reconstitution of SmiRNPâ€EGFâ€H5E using either siKRAS or a variant of siKRAS with the Sm binding sequence 5â€²â€AUUUUUGâ€3â€² replaced with 5â€²â€AAAAAAGâ€3â€² (siKRAS (Sm abs abs S2A S2B S2C abs abs S2Aâ€“C We then tested the stability of the reconstituted SmiRNPâ€EGFâ€H5E complex by incubating it at 4Â Â°C and room temperature for 24Â h and subsequently analyzing it by analytical size exclusion chromatography. The analytical size exclusion chromatography profiles of the complexes incubated at 4Â Â°C and room temperature were similar to that of the freshly assembled SmiRNPâ€EGFâ€H5E control (Figure S3 To characterize the structure of SmiRNPâ€EGFâ€H5E, we performed negative stain electron microscopy of the SmiRNPâ€EGFâ€H5E complex. The negatively stained electron micrographs of SmiRNPâ€EGFâ€H5E presented a homogeneous spread of particles of â‰ˆ80Â Ã… in diameter (Figure 2B 2C S4 2C [  7  9 ] [  7a ] [  7a ] 2D 2D 2.2 SmiRNPâ€EGFâ€H5E Silences KRAS We next sought to demonstrate that the reconstituted SmiRNPâ€EGFâ€H5E complex can silence KRAS G13D [  15 ] m KRAS KRAS 50 m Figure  3 m KRAS KRAS Figure 3 In vitro analyses of the gene silencing efficacy, cancer cell cytotoxicity, and stability of SmiRNPâ€EGFâ€H5E. A) Relative KRAS m n * p *** p m n *** p **** p To verify that the KRAS m 3B As HCT116 cells are Kâ€Rasâ€dependent for viability, [  16 ] KRAS m 50 m 3C m 2.3 Receptorâ€Mediated Endocytosis and Endosomal Escape are Essential for Effective Gene Silencing To probe the mechanisms of siRNA delivery by the SmiRNPâ€EGFâ€H5E complex, we performed fluorescence confocal microscopy studies to visualize the subcellular localization of a 5â€²â€FAMâ€labelled siKRAS when delivered by SmiRNPs. We reconstituted three different versions of SmiRNPs carrying a fluorescentâ€tagged 5â€²â€FAMâ€siKRAS: 1) SmiRNP without EGF and H5E (FAMâ€SmiRNP); 2) SmiRNP with EGF (FAMâ€SmiRNPâ€EGF); and 3) SmiRNP with both EGF and H5E (FAMâ€SmiRNPâ€EGFâ€H5E) (Figure S1Aâ€“C For the 6Â h time point, we observed FAM fluorescence signals in cells treated with FAMâ€SmiRNPâ€EGF and FAMâ€SmiRNPâ€EGFâ€H5E, but not in cells treated with FAMâ€SmiRNP and the FAMâ€siKRAS alone ( Figure  4 4A 4A 4A 4A 4A Figure 4 Cellular uptake of SmiRNPâ€EGFâ€H5E by EGFRâ€mediated endocytosis. A) Coâ€localization studies of SmiRNPs by confocal microscopy. HCT116 cells were incubated with 5â€²â€FAM labelled siKRAS (green) alone or various SmiRNPs containing a 5â€²â€FAM labelled siKRAS (green) for 6 and 18Â h, stained with Hoeschst 33342 (blue) for the nuclei and Lysotracker Red for lysosomes (red) before being visualized by confocal microscopy. Note that cells treated with SmiRNPs containing EGF showed enhanced FAM signals (green) in the cells, indicating cellular uptake, while SmiRNP containing both EGF and H5E did not present coâ€localization of siKRAS (green) and lysosome (red), suggesting endosomal escape. B) Flow cytometry analysis of uptake of SmiRNPs by EGFRâ€positive HCT116 and EGFRâ€null SW620 cells. Error bars represent Â± SEM ( n * p *** p KRAS n **** p We further confirmed that H5E is required for effective Kâ€Ras knockdown by western blot analysis. HCT116 cells incubated with SmiRNPâ€EGFâ€H5E exhibited lower Kâ€Ras levels relative to the buffer control (Figure 3D S1D S1E S1F 3D To quantify the uptake of FAMâ€siKRAS by HCT116, we performed flow cytometry and compared their mean fluorescence intensities (MFI) of cells incubated with FAMâ€siKRAS, FAMâ€SmiRNP, FAMâ€SmiRNPâ€EGF, FAMâ€SmiRNPâ€EGFâ€H5E, and buffer. The results showed that the FAMâ€SmiRNPâ€EGF and FAMâ€SmiRNPâ€EGFâ€H5E samples showed higher MFI (470Â Â±Â 27 and 577Â Â±Â 12, respectively) than SmiRNP (without EGF) (298Â Â±Â 57) while buffer and siKRAS showed very minimal MFIs (27Â Â±Â 5 and 27Â Â±Â 5) (Figure 4B S5 S6A 4B S5 KRAS S6Bâ€“D To demonstrate that SmiRNPâ€EGFâ€H5E can be uptaken by another cell line that expresses EGFR, we tested SmiRNPâ€EGFâ€H5E on a pancreatic cancer cell line (Panc 02.03) that expresses EGFR (Figure S6A KRAS G12D KRAS KRAS 4C 4D 4E KRAS 2.4 SmiRNPâ€EGFâ€H5E Protects siKRAS From Serum Nucleases We then considered the stability of the siKRAS when delivered by SmiRNPâ€EGFâ€H5E via the bloodstream, which contains serum nucleases. [  3a ] 3E 3E 3E 3E 2.5 SmiRNPâ€EGFâ€H5E Suppresses HCT116 Tumor Growth in Mice We ultimately wanted to test the in vivo delivery of siKRAS and KRAS Figure  5 5B KRAS Figure 5 In vivo evaluation of SmiRNPâ€EGFâ€H5E in HCT116 xenograftâ€bearing mice. A) Photos of the collected HCT116 xenografts (left) and weights of the tumors (right) are shown. B) Tumor volumes measured at each injection. C) Body weights of mice during the treatment period. In A) to C), error bars represent Â± SEM ( n  * ** p KRAS n ** p *** p During the treatment period, no animal deaths or significant decrease in animal body weights (Figure 5C S7 S8 The final injection for 3 mice from the siKRAS, SmiRNP, and SmiRNPâ€EGFâ€H5E groups contained a Cy5.5 fluorescent tag on the 5â€²â€end of the siKRAS (Figure S1G,H S9 S3 5D 5D KRAS Our findings indicate that SmiRNPâ€EGFâ€H5E effectively silences KRAS 2.6 SmiRNP can be Customized to Perform Gene Silencing by Targeting Other Receptors To demonstrate that the SmiRNP delivery system can be customized to target different cell surface receptors, we assembled two additional variants of SmiRNPs: 1) SmiRNPâ€FGF1â€H5E (Figure S1I S1J KRAS KRAS m KRAS Figure  6 6B 6C KRAS 6D 6E 6F Figure 6  KRAS KRAS KRAS m n * p ** p **** p 3 Conclusion We demonstrated that the U4 snRNP could be remodeled into an siRNA delivery agent in the form of a ribonucleoprotein complex. Adapting from established methods for snRNP in vitro reconstitution for structural biology studies, [  7  9  17 ] KRAS [  5 ] [  18 ] While the gene silencing efficacy of SmiRNPâ€EGFâ€H5E (IC 50 [  19 ] [  20 ] [  5 ] Because SmiRNPs are heteromultimeric, we fused two different functional modules to the scaffold of the modified snRNP. As each Sm protein is unique, in theory, there are 12 more vacant sites for protein fusion, considering the possibilities of fusing polypeptides onto the Nâ€ and Câ€termini of each Sm protein. Both termini of the Sm protein are exposed on the side of the Sm ring away from the siRNA duplex, and therefore protein fusion would not interfere with RNA binding (Figure S10 1â€95 4 Experimental Section Expression and Purification of HISâ€SUMOâ€SmD1/SmD2, Hisâ€SUMOâ€SmD1/SmD2â€EGF, Hisâ€SUMOâ€SmD1/SmD2â€FGF1 or Hisâ€SUMOâ€SmD1/SmD2â€VEGFâ€A SmD1 was cloned into the pET28a vector with an Nâ€terminal 6xHisâ€SUMO tag. SmD2, SmD2â€EGF, SmD2â€FGF1, or SmD2â€VEGFâ€A was cloned into the pCDFDuetâ€1 (MCS2) vector. The SmD2â€EGF, SmD2â€FGF1, and SmD2â€VEGFâ€A fusion proteins contain a linker with the amino acid sequence GGSGGS in between SmD2 and EGF, FGF1, or VEGFâ€A. The plasmids encoding for SmD1 and SmD2, SmD2â€EGF, SmD2â€FGF1, or SmD2â€VEGFâ€A were coâ€transformed into E. coli 600 m For protein purification, cell pellets were resuspended in lysis buffer (20Â m m m m m m m m m m m m m m m m m m m m Expression and Purification of Hisâ€SmD3/B 1â€95 1â€95 Plasmids pET28a_Hisâ€SmD3 and pCDFDuetâ€1_SmB 1â€95 [  17 ] 1â€95 1â€95 E. coli 600 m The protein purification protocols were adapted from a published report. [  17 ] m m m m âˆ’1 m m m m m m m m m m m m m Expression and Purification of SmGâ€His/SmE/SmF Plasmids pET26b_SmGâ€His and pCDFDuetâ€1_SmE/SmF were provided by Liang Tong. [  17 ] E. coli 1â€95 In vitro Reconstitution of SmiRNPs siRNA (synthesized by Dharmacon, Horizon Discovery) was reannealed in DEPCâ€treated water at 90Â Â°C for 5Â min followed by snapâ€cooling on ice for 10Â min. For the reconstitution of SmiRNPs, 1.5 molar equivalents of the component proteins were mixed with 1 molar equivalent of the siRNA in reconstitution buffer (20Â m m m m m m m m m S1 Negative Stain Electron Microscopy The purified SmiRNPâ€EGFâ€H5E complex was diluted to 0.02Â mgÂ mL âˆ’1 âˆ’1 [  13 ] abâ€initio [  7a ] [  14 ] Cell Culture Human colorectal carcinoma cell lines HCT116 and SW620, as well as human pancreatic adenocarcinoma epithelial cell line Panc 02.03, were purchased from the American Type Culture Collection (ATCC, USA). The HCT116 cells were cultured in McCoy's 5A medium (16600082, Gibco), the SW620 cells were cultured in high glucose Dulbecco's Modified Eagle Medium (DMEM) medium (12100061, Gibco), and the Panc 02.03 cells were cultured in RPMI 1640 medium (31800089, Gibco). All the media were supplemented with 10% fetal bovine serum (FBS, A5256701, Gibco) and 1x Antibioticâ€Antimycotic (15240062, Gibco). All cells were maintained at 37Â Â°C in a humidified atmosphere of 5% CO 2 Quantification of KRAS mRNA Expression Levels Using RTâ€qPCR The HCT116, SW620, or Panc 02.03 cells were treated with indicated concentrations of SmiRNP, SmiRNPâ€EGFâ€H5E, SmiRNPâ€FGF1â€H5E, SmiRNPâ€VEGFâ€Aâ€H5E, component proteins, siKRAS, or buffer. After 48Â h of incubation, the cells were lysed with the TRIzol reagent (Invitrogen). Total RNA was extracted from cells using the Directâ€zol RNA Miniprep Kit (R2052, Zymo Research), following the manufacturer's protocol. 500Â ng of each extracted RNA sample was reverseâ€transcribed into cDNA using the PrimeScript RT Reagent Kit (RR037A, Takara). RTâ€qPCR was performed on a StepOnePlus Realâ€Time PCR instrument (Applied Biosystems) using iTaq Universal SYBR Green Supermix (1725124, Bioâ€Rad). PCR reactions were performed in duplicates at 95Â Â°C for 3Â min, and 95Â Â°C for 15 s, 60Â Â°C for 1Â min, for 40 cycles. For in vivo studies, tumor tissues were homogenized in the TRIzol reagent using a tissue homogenizer (Servicebio, China). The homogenization was carried outÂ in three cycles, each lasting 15Â s at 60Â Hz, with a 10Â s pause between cycles. Total RNA was then extracted and reverseâ€transcribed as described above. RTâ€qPCR analyses were performed in duplicates with the same reaction and thermocycling conditions as described above using a ViiA 7 Real Time PCR System (Applied Biosystems). The primer sequences corresponding to KRAS KRAS ACTB Analyses of Kâ€Ras Protein Levels by Immunoblotting (Western Blot) The HCT116, SW620, or Panc 02.03 cells were treated with indicated concentrations of SmiRNPâ€EGFâ€H5E, SmiRNPâ€FGF1â€H5E, SmiRNPâ€VEGFâ€Aâ€H5E, component proteins, siKRAS, or buffer. After 48Â h of incubation, the cell pellets were harvested, washed with cold PBS, and lysed with the RIPA lysis buffer on ice for 30Â min. The cell lysates were clarified by centrifugation at 15600Â rcf at 4Â Â°C for 15Â min. The protein concentrations were determined using the Quick Start Bradford protein assay kit (5000205, Bioâ€Rad). The samples were subjected to 10% SDSâ€PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (1620177, Bioâ€Rad). The membranes were blocked with 5% blocking buffer (1X Trisâ€buffered saline, 0.1% Tween 20, 5% (w/v) nonfat dry milk) for 1Â h at room temperature. The membranes were then probed with diluted antiâ€Kâ€Ras primary recombinant rabbit mAb (11H35L14, Invitrogen, 1:500), antiâ€Î²â€actin (C4) primary mouse mAb (scâ€47778, Santa Cruz, 1:1000), and antiâ€GAPDH (Gâ€9) primary mouse mAb (scâ€365062, Santa Cruz, 1:1000) at 4Â Â°C overnight. Subsequently, the membranes were washed with Trisâ€buffered saline supplemented with 0.1% Tween 20 (TBST) for 10Â min for a total of three times. The membranes were then probed with corresponding diluted secondary antibodies using goat antiâ€mouse IgG (1706515, Bioâ€Rad, 1:3000) or goat antiâ€rabbit IgG (1721011, Bioâ€Rad, 1:3000) for 1Â h at room temperature. The membranes were washed again with TBST buffer three times. Proteins were visualized by chemiluminescence using Immobilon Forte Western HRP Substrate (WBLUF0500, Millipore) with ChemiDoc imaging System (Bioâ€Rad, USA). The protein bands were further analyzed using Image J. For in vivo studies, tissue lysates were prepared using the RIPA lysis buffer, followed by homogenization. Western blot assays were performed as described above. The primary antibody for Kâ€Ras (11H35L14, Invitrogen, 1:500) was used to probe the membranes. The antiâ€ğ›¼â€actinin (scâ€17829, Santa Cruz, 1:1000) was used as the loading control. Cell Viability Assay The HCT116, SW620, or Panc 02.03 cells were separately treated with SmiRNP, component proteins, siRNA, or buffer at indicated concentrations in triplicate in a 96â€well plate. After 72Â h of incubation, 10Â ÂµL of MTT (3â€[4,5â€dimethylthiazolâ€2â€yl]â€2,5â€diphenylterazolium bromide) solution (5Â mgÂ mL âˆ’1 Confocal Microscopy Imaging HCT116 cells were seeded onto a Âµâ€Dish 35Â mm Quad (80416, Ibidi). The cells were then treated with 150Â n m m R37605 Flow Cytometry HCT116 or SW620 cells were seeded in 24â€well plates at 70%â€“80% confluency and allowed to attach overnight. The cells were then serumâ€starved for 4Â h and treated with 250Â n m Nuclease Protection Assay SmiRNPâ€EGFâ€H5E or siKRAS (600Â n m Stability Analysis of SmiRNPâ€EGFâ€H5E Freshly reconstituted and purified SmiRNPâ€EGFâ€H5E (600Â mL; 1.5Â mg/mL) at 4Â Â°C was split into 3 equal portions. One of the portions was immediately loaded onto a Superdex 200 Increase 10/30 GL column (Cytiva) equilibrated with a buffer containing 20Â mM HEPES pH 7.5, 500Â mM NaCl, 10Â mM EDTA, and 5Â mM DTT for analysis. Another two vials were incubated at 4Â Â°C and room temperature for 24Â h respectively before being subjected to the same analytical size exclusion chromatography for analysis. SmiRNPâ€EGFâ€H5E Reconstitution Test with siKRAS and siKRAS (Sm abs Reconstituted samples (500Â ÂµL) for SmiRNPâ€EGFâ€H5E using siKRAS or siKRAS (Sm abs 1â€95 m m abs m m m m m m m m m Animal Experiments Thirtyâ€two male 8â€weekâ€old BALB/c nu/nu mice with a body weight of 22Â Â±Â 2Â g were purchased from GemPharmatech Co., Ltd (Jiangsu, China). All care and handling of animals were conducted with the approval of the Department of Health, Hong Kong (Licence No.: (21â€188) in DHHT&A/8/2/6 Pt.4). The animal experiment procedures were approved by the Committee on the Use of Human & Animal Subjects of the Hong Kong Baptist University. HCT116 cells (5Â Ã—Â 10 6 âˆ’1 âˆ’1 âˆ’1 âˆ’1 âˆ’1 Statistical Analysis All data, unless otherwise specified, are presented as mean Â± SEM. Comparisons were performed using oneâ€way ANOVA followed by Dunnett's or Tukey's test (as specified) using the GraphPad Prism 10 software. p Conflict of Interest WSA is the inventor of patents 17/930,088 and 110109035. WSA is the founder and director of Nuplex Limited. NYT, XW, and ZLY are coâ€founders and shareholders of Nuplex lImited. Other authors declare no conflict of interest. Supporting information Supporting Information Acknowledgements N.Y.T. and X.W. contributed equally to this work. We thank the Faculty of Science and the Department of Chemisty of Hong Kong Baptist University for funding. We thank Liang Tong for providing plasmids for expression of SmD3/SmB 1â€95 Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. 1 A. Fire S. Xu M. K. Montgomery S. A. Kostas S. E. Driver C. C. Mello Nature 1998 391 806 9486653 10.1038/35888 2 a) S. Y. Wu G. Lopezâ€Berestein G. A. Calin A. K. Sood Sci. Transl. Med. 2014 6 240ps247 10.1126/scitranslmed.3008362 PMC4154139 24920658 b) A. D. Cox S. W. Fesik A. C. Kimmelman J. Luo C. J. Der Nat Rev Drug Discov 2014 13 828 25323927 10.1038/nrd4389 PMC4355017 c) A. L. Hopkins C. R. Groom Nat Rev Drug Discov 2002 1 727 12209152 10.1038/nrd892 3 a) Y. Zhu L. Zhu X. Wang H. Jin Cell Death Dis. 2022 13 644 35871216 10.1038/s41419-022-05075-2 PMC9308039 b) K. Paunovska D. Loughrey J. E. Dahlman Nat. Rev. Genet. 2022 23 265 34983972 10.1038/s41576-021-00439-4 PMC8724758 4 a) T. S. Zimmermann V. Karsten A. Chan J. Chiesa M. Boyce B. R. Bettencourt R. Hutabarat S. Nochur A. Vaishnaw J. Gollob Mol. Ther. 2017 25 71 28129130 10.1016/j.ymthe.2016.10.019 PMC5363199 b) J. B. Porter A. Scrimgeour A. Martinez L. James M. Aleku R. Wilson M. Muckenthaler M. Boyce D. Wilkes U. Schaeper G. V. Campion Am J Hematol 2023 98 1425 37497888 10.1002/ajh.27015 c) M. Balwani E. Sardh P. Ventura P. A. Peiro D. C. Rees U. Stolzel D. M. Bissell H. L. Bonkovsky J. Windyga K. E. Anderson C. Parker S. M. Silver S. B. Keel J. D. Wang P. E. Stein P. Harper D. Vassiliou B. Wang J. Phillips A. Ivanova J. G. Langendonk R. Kauppinen E. Minder Y. Horie C. Penz J. Chen S. Liu J. J. Ko M. T. Sweetser P. Garg N. Engl. J. Med. 2020 382 2289 32521132 10.1056/NEJMoa1913147 d) K. K. Ray R. S. Wright D. Kallend W. Koenig L. A. Leiter F. J. Raal J. A. Bisch T. Richardson M. Jaros P. L. Wijngaard J. J. Kastelein N. Engl. J. Med. 2020 382 1507 e) S. F. Garrelfs Y. Frishberg S. A. Hulton M. J. Koren W. D. O'Riordan P. Cochat G. Deschenes H. Shashaâ€Lavsky J. M. Saland W. G. Van't Hoff D. G. Fuster D. Magen S. H. Moochhala G. Schalk E. Simkova J. W. Groothoff D. J. Sas K. A. Meliambro J. Lu M. T. Sweetser P. P. Garg A. K. Vaishnaw J. M. Gansner T. L. McGregor J. C. Lieske I.â€A. Collaborators N. Engl. J. Med. 2021 384 1216 33789010 10.1056/NEJMoa2021712 5 W. Tai J. Li E. Corey X. Gao Nat. Biomed. Eng. 2018 2 326 30936447 10.1038/s41551-018-0214-1 PMC6136846 6 T. Endoh M. Sisido T. Ohtsuki Bioconjug Chem 2008 19 1017 18442282 10.1021/bc800020n 7 a) A. K. Leung K. Nagai J. Li Nature 2011 473 536 21516107 10.1038/nature09956 PMC3103711 b) C. Preusser Z. Palfi A. Bindereif Eukaryot Cell 2009 8 1228 19542313 10.1128/EC.00090-09 PMC2725569 c) Y. Sun Y. Zhang W. S. Aik X. C. Yang W. F. Marzluff T. Walz Z. Dominski L. Tong Science 2020 367 700 32029631 10.1126/science.aaz7758 PMC7008720 d) Y. Kondo C. Oubridge A. M. van Roon K. Nagai Elife 2015 4 10.7554/eLife.04986 PMC4383343 25555158 8 a) X. C. Yang I. Sabath J. Debski M. Kausâ€Drobek M. Dadlez W. F. Marzluff Z. Dominski Mol. Cell. Biol. 2013 33 28 23071092 10.1128/MCB.00653-12 PMC3536302 b) M. R. Lerner J. A. Boyle S. M. Mount S. L. Wolin J. A. Steitz Nature 1980 283 220 7350545 10.1038/283220a0 c) M. R. Lerner J. A. Steitz Proc Natl Acad Sci U S A 1979 76 5495 316537 10.1073/pnas.76.11.5495 PMC411675 9 A. K. Leung C. Kambach Y. Kondo M. Kampmann M. Jinek K. Nagai J. Mol. Biol. 2010 402 154 20643141 10.1016/j.jmb.2010.07.017 10 C. Kambach S. Walke R. Young J. M. Avis E. de la Fortelle V. A. Raker R. Luhrmann J. Li K. Nagai Cell 1999 96 375 10025403 10.1016/s0092-8674(00)80550-4 11 a) A. Tomas C. E. Futter E. R. Eden Trends Cell Biol. 2014 24 26 24295852 10.1016/j.tcb.2013.11.002 PMC3884125 b) H. S. Wiley J. J. Herbst B. J. Walsh D. A. Lauffenburger M. G. Rosenfeld G. N. Gill J. Biol. Chem. 1991 266 11083 1645724 12 H. LÃ³pezâ€Laguna R. Cubarsi U. Unzueta R. Mangues E. VÃ¡zquez A. Villaverde Sci. China Mater. 2020 63 644 13 A. Punjani J. L. Rubinstein D. J. Fleet M. A. Brubaker Nat. Methods 2017 14 290 28165473 10.1038/nmeth.4169 14 T. C. Terwilliger P. D. Adams P. V. Afonine O. V. Sobolev Nat. Methods 2018 15 905 30377346 10.1038/s41592-018-0173-1 PMC6214191 15 a) S. A. Kennedy M. A. Jarboui S. Srihari C. Raso K. Bryan L. Dernayka T. Charitou M. Bernalâ€Llinares C. Herreraâ€Montavez A. Krstic D. Matallanas M. Kotlyar I. Jurisica J. Curak V. Wong I. Stagljar T. LeBihan L. Imrie P. Pillai M. A. Lynn E. Fasterius C. Alâ€Khalili Szigyarto J. Breen C. Kiel L. Serrano N. Rauch O. Rukhlenko B. N. Kholodenko L. F. Iglesiasâ€Martinez Nat. Commun. 2020 11 499 31980649 10.1038/s41467-019-14224-9 PMC6981206 b) J. Y. Guo H. Y. Chen R. Mathew J. Fan A. M. Strohecker G. Karsliâ€Uzunbas J. J. Kamphorst G. Chen J. M. Lemons V. Karantza H. A. Coller R. S. Dipaola C. Gelinas J. D. Rabinowitz E. White Genes Dev. 2011 25 460 21317241 10.1101/gad.2016311 PMC3049287 16 S. Alves L. Castro M. S. Fernandes R. Francisco P. Castro M. Priault S. R. Chaves M. P. Moyer C. Oliveira R. Seruca M. Corteâ€Real M. J. Sousa A. Preto Oncotarget 2015 6 30787 26418750 10.18632/oncotarget.5021 PMC4741568 17 K. Bucholc W. S. Aik X. C. Yang K. Wang Z. H. Zhou M. Dadlez W. F. Marzluff L. Tong Z. Dominski Nucleic Acids Res. 2020 48 1508 31819999 10.1093/nar/gkz1148 PMC7026596 18 a) S. Bhattacharya A. Mohanty S. Achuthan S. Kotnala M. K. Jolly P. Kulkarni R. Salgia Trends Cancer 2021 7 323 33622644 10.1016/j.trecan.2021.01.009 PMC8500356 b) A. Mohanty A. Nam S. Srivastava J. Jones B. Lomenick S. S. Singhal L. Guo H. Cho A. Li A. Behal T. Mirzapoiazova E. Massarelli M. Koczywas L. D. Arvanitis T. Walser V. Villaflor S. Hamilton I. Mambetsariev M. Sattler M. W. Nasser M. Jain S. K. Batra R. Soldi S. Sharma M. Fakih S. K. Mohanty A. Mainan X. Wu Y. Chen Y. He Sci. Adv. 2023 9 ade3816 10.1126/sciadv.ade3816 PMC10575592 37831779 19 B. Dalby S. Cates A. Harris E. C. Ohki M. L. Tilkins P. J. Price V. C. Ciccarone Methods 2004 33 95 15121163 10.1016/j.ymeth.2003.11.023 20 C. Liufu Y. Li J. Tu H. Zhang J. Yu Y. Wang P. Huang Z. Chen Int J Nanomedicine 2019 14 8923 31814720 10.2147/IJN.S217338 PMC6863126 ",
  "metadata": {
    "Title of this paper": "Development of a Modular Ribonucleoprotein Complex as a General Strategy to Deliver RNAi Therapeutics",
    "Journal it was published in:": "Advanced Healthcare Materials",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12477566/"
  }
}